<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01809704</url>
  </required_header>
  <id_info>
    <org_study_id>DC-03267</org_study_id>
    <nct_id>NCT01809704</nct_id>
  </id_info>
  <brief_title>Clinical Validation of New OCT System</brief_title>
  <official_title>Topcon DRI OCT-1 Optical Coherence Tomography System for the Acquisition of Retinal Thickness Measurements and Ocular Images of the Posterior Chamber: Agreement and Precision Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Topcon Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Topcon Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate clinical substantial equivalence of DRI OCT-1 as comparable to the
      commercially available Cirrus
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal Thickness</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Normal and Ocular Pathology.</condition>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <description>Normal results from clinical exam and free of ocular pathology.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucoma</arm_group_label>
    <description>Clinical exam results consistent with glaucoma and visual field defects consistent with glaucoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retina</arm_group_label>
    <description>Clinical exam results consistent with retina pathology</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects that are Normal, or shows signs of Glaucoma or Retinal Ocular Pathology.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Normal Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate as
             evidenced by signing the informed consent

          3. Subjects presenting at the site with normal eyes (eyes without pathology)

          4. IOP â‰¤ 21 mmHg bilaterally

          5. BCVA 20/40 or better bilaterally

          6. Both eyes must be free of eye disease

        Exclusion Criteria for Normal Group

          1. Subjects unable to tolerate ophthalmic imaging

          2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

          3. HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT
             'Outside Normal Limits' and/or PSD &lt; 1%

          4. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on
             manufacturer's recommendation), defined as fixation losses &gt; 33% or false positives &gt;
             25%, or false negatives &gt; 25%

          5. Presence of any ocular pathology except for cataract

          6. Previous ocular surgery or laser treatment other than uncomplicated refractive
             procedure or cataract surgery performed within six months prior to study scanning

          7. Narrow angle

          8. History of leukemia, dementia or multiple sclerosis

          9. Concomitant use of hydroxychloroquine and chloroquine

        Inclusion Criteria for Glaucoma Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate as
             evidenced by signing the informed consent

          3. Subjects presenting at the site with glaucoma

          4. BCVA 20/40 or better in the study eye

          5. HFA visual field (24-2 Sita Standard, white on white) result abnormal, defined as GHT
             'Outside Normal Limits' and/or PSD &lt; 1% in the study eye

        Exclusion Criteria for Glaucoma Group

          1. Subjects unable to tolerate ophthalmic imaging

          2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

          3. HFA visual field (24-2 Sita Standard, white on white) result unreliable, defined as
             fixation losses &gt; 33% or false positives &gt; 25%, or false negatives &gt; 25% in the study
             eye

          4. Presence of any ocular pathology except glaucoma in the study eye

          5. Previous ocular surgery or laser treatment other than uncomplicated procedures
             performed within six months prior to study scanning in the study eye

          6. History of leukemia, dementia or multiple sclerosis

          7. Concomitant use of hydroxychloroquine and chloroquine

        Inclusion Criteria for Retina Disease Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate as
             evidenced by signing the informed consent

          3. Subjects presenting at the site with retinal disease

          4. IOP &lt;= 21 mmHg in the study eye

          5. BCVA 20/400 or better in the study eye

          6. Diagnosis of some type of retinal pathology by investigator, may include, but not
             limited to: Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy,
             Macular Hole, Epiretinal Membrane, Cystoid Macula Edema, and others

        Exclusion Criteria for Retinal Disease Group

          1. Subjects unable to tolerate ophthalmic imaging

          2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

          3. Presence of glaucoma or any ocular pathology other than a Retinal pathology (e.g.,
             cornea pathology) in the study eye

          4. Previous ocular surgery or laser treatment other than uncomplicated procedures
             performed within six months prior to study scanning in the study eye

          5. Narrow angle in the study eye

          6. History of leukemia, dementia or multiple sclerosis

          7. Concomitant use of hydroxychloroquine and chloroquine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Sinai, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Clinical Marketing</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton Glaucoma Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Murray Fingeret</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreous Retina Macula Consultants of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2013</study_first_submitted>
  <study_first_submitted_qc>March 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2013</study_first_posted>
  <last_update_submitted>January 22, 2014</last_update_submitted>
  <last_update_submitted_qc>January 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

